XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 80 filers reported holding XENON PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $611,000 | -21.8% | 20,000 | -20.0% | 0.13% | -3.0% |
Q4 2021 | $781,000 | -61.9% | 25,000 | -77.3% | 0.13% | +73.7% |
Q2 2021 | $2,048,000 | +63.4% | 110,000 | +57.1% | 0.08% | +61.7% |
Q1 2021 | $1,253,000 | -41.5% | 70,000 | -49.8% | 0.05% | -57.3% |
Q4 2020 | $2,143,000 | +36.7% | 139,360 | -1.6% | 0.11% | +29.4% |
Q3 2020 | $1,568,000 | -11.7% | 141,660 | 0.0% | 0.08% | -5.6% |
Q2 2020 | $1,776,000 | +10.6% | 141,660 | 0.0% | 0.09% | -90.1% |
Q1 2020 | $1,606,000 | -55.1% | 141,660 | -48.0% | 0.91% | +62.5% |
Q4 2019 | $3,573,000 | +33.8% | 272,543 | -8.1% | 0.56% | +33.5% |
Q3 2019 | $2,671,000 | -10.7% | 296,500 | -2.2% | 0.42% | +106.9% |
Q2 2019 | $2,991,000 | -3.0% | 303,300 | 0.0% | 0.20% | -32.2% |
Q1 2019 | $3,082,000 | +92.9% | 303,300 | +19.7% | 0.30% | -7.7% |
Q4 2018 | $1,598,000 | -73.9% | 253,300 | -45.4% | 0.32% | -20.6% |
Q3 2018 | $6,129,000 | +38.2% | 464,300 | -3.7% | 0.41% | +2.5% |
Q2 2018 | $4,436,000 | – | 482,200 | – | 0.40% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |